Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Int Immunopharmacol ; 135: 112294, 2024 Jun 30.
Article de Anglais | MEDLINE | ID: mdl-38776856

RÉSUMÉ

Diabetic nephropathy (DN) is the most frequent and serious complication of type 2 diabetes (T2DM). Lack of a precise remedy and socio-economic burden of DN patients implements searching about alternative therapies. This study aims to evaluate the possible beneficial effect of alpha-lipoic acid (α-LA) alone or in combination with metformin (Met) in ameliorating STZ/High fat diet (HFD)-induced DN. T2DM was induced via HFD administration for 15 weeks and single ip injection of STZ (35 mg/kg) at week 7. Male Sprague-Dawley rats were randomly grouped as follows: control group, STZ/HFD-induced DN, Met/T; daily treated with 150 mg/kg Met, α-LA/T group; daily treated with 100 mg/kg α-LA, and Met/T + α-LA/T group; daily treated with Met and α-LA at same doses. Administration of Met and α-LA succeeded in attenuating STZ/HFD-induced DN as manifested by significant decrease in kidney weight as well as renal and cardiac hypertrophy index. Moreover, Met and α-LA improved glycemic control, kidney functions and lipid profile as well as restored redox balance. Additionally, Met and α-LA administration significantly upregulated PTEN level accompanied by significant downregulation in renal p-AKT and miR-29a levels. Histopathologically, Met and α-LA administration mitigated STZ/HFD-induced histopathological alterations in kidney and heart. Moreover, immunohistochemical examination revealed a significant decrease in renal YAP, collagen I and Ki-67. Taken together, these observations revealed that Met and α-LA administration could protect against STZ/HFD-induced DN.


Sujet(s)
Diabète expérimental , Néphropathies diabétiques , Metformine , microARN , Phosphohydrolase PTEN , Protéines proto-oncogènes c-akt , Rat Sprague-Dawley , Acide lipoïque , Protéines de signalisation YAP , Animaux , Acide lipoïque/usage thérapeutique , Acide lipoïque/pharmacologie , Metformine/pharmacologie , Metformine/usage thérapeutique , Mâle , Néphropathies diabétiques/traitement médicamenteux , Néphropathies diabétiques/métabolisme , Néphropathies diabétiques/anatomopathologie , microARN/métabolisme , microARN/génétique , Phosphohydrolase PTEN/métabolisme , Phosphohydrolase PTEN/génétique , Protéines de signalisation YAP/métabolisme , Protéines proto-oncogènes c-akt/métabolisme , Diabète expérimental/traitement médicamenteux , Diabète expérimental/métabolisme , Rats , Transduction du signal/effets des médicaments et des substances chimiques , Rein/effets des médicaments et des substances chimiques , Rein/anatomopathologie , Rein/métabolisme , Diabète de type 2/traitement médicamenteux , Diabète de type 2/métabolisme , Alimentation riche en graisse , Association de médicaments , Hypoglycémiants/usage thérapeutique , Hypoglycémiants/pharmacologie , Streptozocine
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...